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Abstract
Background: Studies have shown that metallothionein 3 (MT-3) is not expressed in normal urothelium or in the
UROtsa cell line, but is expressed in urothelial cancer and in tumors generated from the UROtsa cells that have
been transformed by cadmium (Cd
+2) or arsenite (As
+3).The present study had two major goals. One, to determine
if epigenetic modifications control urothelial MT-3 gene expression and if regulation is altered by malignant
transformation by Cd
+2 or As
+3. Two, to determine if MT-3 expression might translate clinically as a biomarker for
malignant urothelial cells released into the urine.
Results: The histone deacetylase inhibitor MS-275 induced MT-3 mRNA expression in both parental UROtsa cells
and their transformed counterparts. The demethylating agent, 5-Aza-2’-deoxycytidine (5-AZC) had no effect on MT-
3 mRNA expression. ChIP analysis showed that metal-responsive transformation factor-1 (MTF-1) binding to metal
response elements (MRE) elements of the MT-3 promoter was restricted in parental UROtsa cells, but MTF-1
binding to the MREs was unrestricted in the transformed cell lines. Histone modifications at acetyl H4, trimethyl
H3K4, trimethyl H3K27, and trimethyl H3K9 were compared between the parental and transformed cell lines in the
presence and absence of MS-275. The pattern of histone modifications suggested that the MT-3 promoter in the
Cd
+2 and As
+3 transformed cells has gained bivalent chromatin structure, having elements of being
“transcriptionally repressed” and “transcription ready”, when compared to parental cells. An analysis of MT-3
staining in urinary cytologies showed that a subset of both active and non-active patients with urothelial cancer
shed positive cells in their urine, but that control patients only rarely shed MT-3 positive cells.
Conclusion: The MT-3 gene is silenced in non-transformed urothelial cells by a mechanism involving histone
modification of the MT-3 promoter. In contrast, transformation of the urothelial cells with either Cd
+2 or As
+3
modified the chromatin of the MT-3 promoter to a bivalent state of promoter readiness. Urinary cytology for MT-3
positive cells would not improve the diagnosis of urothelial cancer, but might have potential as a biomarker for
tumor progression.
Background
This laboratory has proposed the third isoform of the
metallothionein gene family as a potential biomarker
for the development of human bladder cancer [1,2].
This was first suggested by a retrospective immunohis-
tochemical analysis of MT-3 expression on a modest
sample set of archival diagnostic specimens composed
of benign and cancerous lesions of the bladder [1].
The cells of the normal bladder were shown to have
no immunoreactivity for the MT-3 protein, and no
expression of MT-3 mRNA or protein were noted in
extracts prepared from samples from surgically
removed normal bladder tissue. In contrast, all speci-
mens of urothelial cancer were immunoreactive for the
MT-3 protein, and the intensity of staining correlated
to tumor grade. This was later expanded to a more
robust retrospective study using archival diagnostic tis-
sue [2]. This study showed that only 2 of 63 (3.17%)
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taining for the MT-3 protein. In contrast, 103 of 107
(96.26%) high grade urothelial cancers and 17 of 17
(100%) specimens of carcinoma in situ stained positive
for the MT-3 protein. For low grade urothelial cancer,
30 of 48 specimens (62.5%) expressed the MT-3
protein.
T h el a b o r a t o r yh a su s e dt h eU R O t s ac e l ll i n ea sa
model system to elucidate the differences in the
expression of the MT-3 gene between normal and
malignant urothelium. The UROtsa cell line is derived
from a primary culture of human urothelial cells that
was immortalized using the SV40 large T-antigen [3,4].
The UROtsa cells retain a normal cytogenetic profile,
grow as a contact inhibited monolayer, and are not
tumorigenic as judged by the inability to form colonies
in soft agar and tumors in nude mice. This laboratory
showed that UROtsa cells grown in a serum-free
growth medium displayed features consistent with the
intermediate layer of the urothelium [5]. Identical to
that of normal in situ urothelium, the UROtsa cell line
was shown to have no basal expression of MT-3
mRNA or protein. The laboratory has also directly
malignantly transformed the UROtsa cell line by expo-
sure to Cd
+2 or As
+3 and shown that the tumor trans-
plants produced by the transformed cells had
histologic features consistent with human urothelial
cancer [6]. An interesting finding in subsequent studies
was that MT-3 mRNA and protein was not expressed
in the Cd
+2 and As
+3 transformed cell lines, but was
expressed in the tumor transplants generated by these
cell lines in immunocompromised mice [2]. That this
was not an anomaly of the UROtsa cell line was sug-
gested by identical findings between cell lines and
tumor transplants for the MCF-7, T-47 D, Hs 578T,
MDA-MB-231 breast cancer cell lines and the PC-3
prostate cancer cell lines [2]. The first goal of the pre-
sent study was to determine if epigenetic modifications
were responsible for gene silencing of MT-3 in the
parental UROtsa cell line. The second goal of the
study was to determine if the accessibility of the MRE
of the MT-3 promoter to the MTF-1 transcription fac-
tor was different between the parental UROtsa cell line
and the UROtsa cell lines malignantly transformed by
either Cd
+2 or As
+3. The third goal was to determine if
histone modifications were different between the par-
ental UROtsa cell line and the transformed cell lines.
The last goal was to perform a preliminary analysis to
determine if MT-3 expression might translate clinically
as a possible biomarker for malignant urothelial cells
released into the urine by patients with urothelial
cancer.
Results
MT-3 mRNA expression following treatment of parental
UROtsa cells and their Cd
+2 and As
+3 transformed
counterparts with inhibitors of DNA methylation and
acetylation
The parental and transformed UROtsa cells were treated
with the histone deacetylase inhibitor, MS-275, and the
methylation inhibitor 5-AZC, to determine the possible
role of histone modifications and DNA methylation on
MT-3 mRNA expression. In the initial determinations,
subconfluent cells were treated with either MS-275 or
5-AZC and allowed to proliferate to confluency, at
which time they were harvested for the determination of
MT-3 mRNA expression. Thisa n a l y s i sd e m o n s t r a t e d
that parental UROtsa cells treated with MS-275
expressed increased levels of MT-3 mRNA compared to
control cells (Figure 1A, D). There was a dose response
relationship with a peak in MT-3 expression at a 10 μM
concentration of MS-275, the highest concentration
which showed no toxicity and allowed the cells to attain
confluency. MS-275 was dissolved in DMSO and it was
shown that DMSO had no effect on MT-3 mRNA
expression in parental UROtsa cells (data not shown).
An identical treatment of the Cd
+2 and As
+3 trans-
formed UROtsa cells with MS-275 also demonstrated
increased MT-3 mRNA levels and a similar dose
response relationship to that of the parental cells (Figure
1B, C, D). The increase in MT-3 mRNA expression due
to MS-275 treatment was several fold greater in the
Cd
+2 and As
+3 transformed UROtsa cells compared to
that of the parental cells. It was also shown that DMSO
h a dn oe f f e c to nM T - 3e x p r e s s i o ni nt h et r a n s f o r m e d
cell lines and that MS-275 had no toxicity similar to
that of the parental cells. In contrast, a similar treatment
of the parental UROtsa cells or their transformed coun-
terparts with the demethylating agent, 5-AZC, had no
e f f e c to nt h ee x p r e s s i o no fM T - 3m R N Ao v e rt h a to f
untreated cells (Figure 1A-D). Concentrations of 5-AZC
were tested up to and including those that inhibited cell
proliferation and no increase in MT-3 expression was
found at any concentration.
A second determination was performed to determine
if initial treatment of the parental and transformed
UROtsa cells with MS-275 would allow MT-3 mRNA
expression to continue after removal of the drug. In this
experiment, the cells were treated with MS-275 as
above, but the drug was removed when the cells
attained confluency and MT-3 expression determined
24 h after drug removal. This determination showed
that MT-3 expression was still elevated following drug
removal for the parental UROtsa cells and their trans-
formed counterparts, albeit, at modestly reduced levels
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Page 2 of 14of expression for all three cell lines (Figure 2A-C). There
was no difference in the degree of reduction of MT-3
expression between the cells lines nor between the treat-
ment and recovery periods.
Differences in zinc induction of MT-3 mRNA expression
between normal and transformed UROtsa cells following
inhibition of histone deacetylase activity
As described above, the parental and transformed
UROtsa cells were allowed to proliferate to confluency in
the presence of MS-275 and then allowed to recover for
24 h in the absence of the drug. After the recovery per-
iod, the cells were then exposed to 100 μMz i n cf o r2 4h
and prepared for the analysis of MT-3 mRNA expression.
The parental UROtsa cells previously exposed to MS-275
showed no increase in MT-3 mRNA expression when
treated with 100 μMZ n
+2 for 24 h (Figure 3A, D). In
contrast, MT-3 expression was induced over a 100 fold
when the Cd
+2 and As
+3 transformed cell lines that had
been previously treated with MS-275 were exposed to
100 μMZ n
+2 (Figure 3B, C, D).
Histone modifications associated with the MT-3 promoter
in the UROtsa parent and transformed cell lines
Two regions of the MT-3 promoter were analyzed for his-
tone modifications before and after treatment of the
respective cell lines with MS-275. These were chosen to
be regions containing sequences of the known metal
response elements. The first region chosen spans the lar-
gest cluster of MREs (MREc, d, e, and MREf) and is desig-
nated as region 1. The second region is immediately
upstream from region 1, extends up to and includes
MREg and is designated region 2 (Figure 4). The level of
acetyl H4, trimethyl H3K4, trimethyl H3K9 and trimethyl
H3K27 modifications were determined for each of the two
regions of the MT-3 promoter using ChIP-qPCR. In the
distal region 2, it was shown that the modification of acetyl
H4 was increased in the parental UROtsa cells and both
transformed cell lines following treatment with MS-275
(Figure 5A-E). For all three cell lines, there was only a
marginal modification for acetyl H4 in cells not treated
with MS-275. In addition, the relative increase in acetyl
H4 modification following MS-275 treatment was greater
in the Cd
+2 and As
+3 transformed cell line compared to
parental cells. There was modification of trimethyl H3K4
in both the normal and transformed UROtsa cell lines
under basal conditions and the level of modification
increased for the parental UROtsa cells and the Cd
+2
transformed cell line following treatment with MS-275
(Figure 5B, E). There was no increase in the level of modi-
fication of H3K4 following MS-275 treatment of the As
+3
transformed UROtsa cells. Modification of trimethyl
Figure 1 Expression of MT-3 mRNA in UROtsa parent, Cd
+2 and As
+3 transformed cell lines. UROtsa parent and the transformed cell lines
were seeded at a 1:10 ratio in the presence of MS-275 till they reached confluency and the expression of MT-3 was determined by RT-PCR
analysis. A. Real time PCR analysis of MT-3 in UROtsa parent cells. B. Real time PCR analysis of MT-3 in Cd
+2 transformed UROtsa cells. C. Real
time PCR analysis of MT-3 in As
+3 transformed UROtsa cells. The expression of MT-3 was normalized to that of b-actin. The determinations were
performed in triplicates and the results shown are the mean ± SE. * Statistically significant compared to untreated control cells. D. Ethidium
bromide stained gel showing the expression of MT-3 in the UROtsa cell lines by semiquantitativePCR.
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Page 3 of 14Figure 2 Expression of MT-3 in parent, Cd
+2 and As
+3 transformed cells after removal of MS-275. Cells were cultured with 10 μM MS-275
until they reached confluency after which the drug was removed and the cells were allowed to recover for 24 h following which RNA was
extracted from the recovered cells. A. RT-PCR analysis of MT-3 expression in UROtsa parent cells. B. RT-PCR analysis of MT-3 expression in Cd
+2
transformed UROtsa cells. C. RT-PCR analysis of MT-3 expression in As
+3 transformed UROtsa cells. Graphs represent real time RT-PCR data
whereas ethidium bromide stained gels show the semiquantitative PCR analysis data. The expression of MT-3 was normalized to that of b-actin.
The determinations were performed in triplicates and the results shown are the mean ± SE.*Statistically significant compared to untreated
control cells.
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Page 4 of 14H3K9 was present in both the parental and transformed
UROtsa cells under basal conditions (Figure 5C, E). The
basal level of H3K9 modification was increased for both
transformed cell lines when compared to parental cells
and also when the As
+3 transformed cell line was com-
pared to the Cd
+2 transformed cell line. There was a dif-
ferential response in the level of H3K9 modification when
the cells were treated with MS-275. The parental UROtsa
cells showed an increase in the modification of H3K9
following MS-275 treatment; whereas, both transformed
cell lines showed a decrease in the level of H3K9 modifica-
tion. The relative magnitude of these differences was large
for the parental and As
+3 transformed cell lines. There
w a sal a r g ed i f f e r e n c ei nt h el e v e lo fm o d i f i c a t i o no f
H3K27 between the parental and the transformed cell
lines, with the parent having a very low level and the
transformed lines highly elevated in their modification of
H3K27 (Figure 5D, E). Treatment of both the Cd
+2 and
Figure 3 Effect of Zn
+2 on MT-3 levels in the parent and transformed UROtsa cell lines. UROtsa parent and the transformed cell lines were
seeded at a 1:10 ratio in the presence of MS-275 until they reached confluency, following which the cells were allowed to recover for 24 h
without the drug. The cells were then exposed to 100 μM zinc for 24 h and RNA was extracted. A. Real time RT-PCR analysis of MT-3 expression
in UROtsa parent cells. B. Real time RT-PCR analysis of MT-3 expression in Cd
+2 transformed UROtsa cells. C. Real time RT-PCR analysis of MT-3
expression in As
+3 transformed UROtsa cells. The expression of MT-3 was normalized to that of b-actin. The determinations were performed in
triplicates and the results shown are the mean ± SE.*Statistically significant compared to untreated control cells. D. Ethidium bromide stained gel
showing the expression of MT-3 in the UROtsa cell lines using semiquantitativePCR.
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+3 transformed cell lines with MS-275 resulted in a
large decrease in the level of H3K27 modification; return-
ing to a level similar to that found in parental cells.
In themore proximal, down-stream promoter region 1,
the modification pattern of acetyl H4 was similar to that
of region 2, with the exception that the basal level of
modification was increased in the Cd
+2 and As
+3 trans-
formed cell lines (Figure 6A, E). The modification pat-
tern of trimethyl H3K4 was also similar between the
two promoter regions with only subtle alterations in the
level of modification (Figure 6B, E). The pattern of tri-
methyl H3K9 modification was also similar between the
two promoter regions, with the exception that the basal
modification of trimethyl H3K9 was increased in the Cd
+2 transformed cell line (Figure 6C, E). There were sig-
nificant differences in the modification of trimethyl
H3K27 between the two promoter regions from the cell
lines. There was modification of trimethyl H3K27 in the
parental UROtsa cells in the absence of MS-275 treat-
ment and the level of modification did not change with
MS-275 treatment (Figure 6D, E). The extent of modifi-
cation of trimethyl H3K27 in the Cd
+2 transformed cells
was identical to the parental cells. The modification of
trimethyl H3K27 was reduced by MS-275 treatment in
the As
+3 transformed cells, but to a lesser degree than
noted for the proximal promoter.
Histone modification and competency of MTF-1 binding
to the MREs of the MT-3 promoter in normal and
transformed UROtsa cells
The ability of MTF-1 to bind the MRE elements of the
MT-3 promoter was determined in the parental UROtsa
cell line and the Cd
+2 and As
+3 transformed cell lines
before and after treatment with MS-275. Primers were
designed to break the MREs down to as many individual
measureable units as possible. Only specific primers for
three regions were possible as designated in Figure 1.
The results of this analysis showed that there was little
or no binding of MTF-1 to the MREa or MREb
sequences in the MT-3 promoter of the parental
UROtsa cells with or without treatment with MS-275
(Figure 7A). In contrast, the MREa, b elements of MT-3
promoter in the Cd
+2 and As
+3 transformed cell lines
were able to bind MTF-1 under basal conditions and
with increased efficiency following treatment with MS-
275 (Figure 7A). A similar analysis of the MREc element
in the MT-3 promoter showed a low amount of MTF-1
binding to parental UROtsa cells not treated with MS-
275 and a significant increase in binding following treat-
ment with MS-275 (Figure 7B). The Cd
+2 and As
+3
transformed cell lines showed appreciable MTF-1 bind-
ing to the MREc element of the MT-3 promoter in the
absence of MS-275 when compared to the parental
UROtsa cells. Treatment with MS-275 had no further
effect on MTF-1 binding to the MREc element of the
MT-3 promoter for the Cd
+2 transformed cells and only
a small increase for the As
+3 transformed cells (Figure
7B). There was no binding of the MTF-1 to the MREe,
f, g elements of the MT-3 promoter for parental
UROtsa cells unexposed to MS-275 (Figure 7C). In con-
trast, there was binding when the parental UROtsa cells
were treated with MS-275. There was binding of MTF-1
to the MREe, f, g elements of the MT-3 promoter in
both Cd
+2 and As
+3 transformed cell lines under control
conditions and a further increase in binding when the
cell lines were treated with MS-275 (Figure 7C).
Figure 4 Schematic illustration of the MT-3 promoter. The distributions of the MREs and the designated amplified regions are indicated.
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Page 6 of 14Figure 5 MT-3 promoter (region 2) associated histone modifications in the cell lines after treatment with MS-275.A - D .C h I P - q P C Ro f
acetyl H4, trimethy H3K4, trimethyl H3K9 and trimethyl H3K27 at the MT-3 promoter using primers for region 2. The amplification value of the
immunoprecipitated DNA was normalized to percentage of input (non-precipitated DNA). The determinations were performed in triplicates and
the results shown are the mean ± SE.*Statistically significant compared to untreated control cells. E. Ethidium bromide stained gel showing the
amplification of the histone modifications using semiquantitative PCR.
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Page 7 of 14Figure 6 MT-3 promoter (region 1) associated histone modifications in the cell lines after treatment with MS-275.A - D .C h I P - q P C Ro f
acetyl H4, trimethy H3K4, trimethyl H3K9 and trimethyl H3K27 at the MT-3 promoter using primers for region 1. The amplification value of the
immunoprecipitated DNA was normalized to percentage of input (non-precipitated DNA). The determinations were performed in triplicates and
the results shown are the mean ± SE.*Statistically significant compared to untreated control cells. E. Ethidium bromide stained gel showing the
amplification of the histone modifications using semiquantitative PCR.
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Page 8 of 14Figure 7 Recruitment of MTF-1 to the MREs of the MT-3 promoter after treatment with MS-275. UROtsa parent and transformed cells
were seeded at a 1:10 ratio and were grown in the presence of 10 μM MS-275 until they reached confluency. They were then exposed to 100
μMZ n
+2 for 4 h and the chromatin was immunoprecipitated with the MTF-1 antibody. PCR was performed with primers specific to each region
as specified in Table 2 and Figure 4 to assess the level of precipitated sequences. A. ChIP-q PCR analysis of MTF-1 recruitment to MRE a and
MREb. B. ChIP-q PCR analysis of MTF-1 recruitment to MRE-c. C. ChIP-q PCR analysis of MTF-1 recruitment to MREe, MREf and MREg. The
amplification value of the immunoprecipitated DNA was normalized to percentage of input (non-precipitated DNA). The determinations were
performed in triplicates and the results shown are the mean ± SE.*Statistically significant compared to untreated control cells. Graphs represent
real time PCR data whereas ethidium bromide stained gels represent semiquantitative PCR data.
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Page 9 of 14Presence of MT-3 positive cells in urinary cytologies of
patients with bladder cancer
Urine samples were collected and urinary cytologies pre-
pared over a 5 year period on patients attending the reg-
ularly scheduled urology clinic. A total of 276 urine
specimens were collected in the study with males com-
prising 67% of the total samples and the average patient
age was 70.4 years with a distribution of 20 to 90 years
of age. The control group was defined as individuals
attending the urology clinic for any reason other than a
suspicion of bladder cancer. A total of 117 control sam-
ples were collected and of these 60 had cells that could
be evaluated by urinary cytology and 57 control samples
provided no cells. Only 3 specimens from the control
group were found to contain cells that were immunos-
tained for the MT-3 protein (Table 1). Urinary cytolo-
gies for 127 patients with a previous history of
urothelial cancer, but with no evidence of active disease,
were examined and 45 were found to have MT-3
stained cells in their urine. No evidence of active disease
w a sd e f i n e db yan e g a t i v ee x a m i n a t i o no ft h eb l a d d e r
using cystoscopy (Table 1). There were 32 patients that
were confirmed to have active disease by cystoscopy and
of these, 19 were found to have MT-3 positive cells by
urinary cytology (Table 1). There were significant differ-
ences between the control and recurrence group of
patients, the control versus non recurrence group and
the recurrence versus no recurrence group as deter-
mined by the Pearson Chi-square test.
There were 90 patients in the study (115 urine cytolo-
gies) that had either multiple urine collections on return
visits to the clinic, or who had previously provided a
urine specimen and later returned to the clinic for fol-
low-up but without providing a urine specimen for the
study. These were able to be followed for recurrence of
urothelial cancer from 2 months up to 59 months. This
allowed an analysis of 18 recurrences and 29 non-recur-
rences in those yielding cytologies with MT-3 positive
cells and 7 recurrences and 24 non-recurrences in those
yielding cytologies with no MT-3 positive cells. A com-
parison of the time to recurrence between these two
groups revealed a significant statistical difference (log
rank 5.067, p = 0.024 and Tarone-Ware 5.071, p =
0.024) between those with urinary cytologies with MT-3
staining cells and those with no MT-3 staining cells
(Figure 8).
Discussion
The initial goal of this study was to determine if epige-
netic modification was responsible for the silencing of
the MT-3 gene in the parental UROtsa cell line. Treat-
ment of the parental UROtsa cells with 5-AZC, a com-
monly used agent to determine DNA methylation status,
was shown to have no effect on MT-3 mRNA expres-
s i o n .T h i sp r o v i d e se v i d e n c et h a tt h eM T - 3g e n ew a s
not silenced by a mechanism involving DNA methyla-
tion in the parental UROtsa cells. The treatment of the
cells with MS-275, a histone deacetylase inhibitor, was
shown to result in the expression of MT-3 mRNA by
the parental UROtsa cell line. MS-275 has been shown
to preferentially inhibit HDAC 1 compared to HDAC 3
and has little or no effect on HDAC 6 and 8 [7-9]. This
finding provides strong evidence that MT-3 expression
is silenced in the parental UROtsa cell line through a
mechanism involving histone modification. The MT-3
gene is also silent in cell lines derived from the UROtsa
parent that have been malignantly transformed by either
Cd
+2 or As
+3 [2,6]. A pattern of MT-3 mRNA expres-
sion similar to that for the parental UROtsa cells was
found following treatment of the Cd
+2 and As
+3 trans-
formed cell lines with 5-AZC and MS-275. The only
exception being that the expression of MT-3 mRNA
was several fold higher following MS-275 treatment in
the Cd
+2 and As
+3 transformed cell lines compared to
the parental UROtsa cells. These findings suggest that
MT-3 gene expression is silenced in both the parental
UROtsa cells and the Cd
+2 and As
+3 transformed
Table 1 MT-3 expression in urinary cytology specimens
Group n MT-3 positive (%) Percentage
Control
a,
b 117 3 2.6
Inactive Disease
a,
c 127 45 35.4
Active Disease
b,
c 32 19 59.4
aControl vs. Active; Pearson Chi-square 33.91 p = 0.000.
bControl vs. Inactive; Pearson Chi-square 19.78 p = 0.000.
cActive vs. Inactive; Pearson Chi-square6.09p = 0.014.
Figure 8 Kaplan Meier plot demonstrating prolonged survival
of MT-3 negative bladder cancer. The survival distributions
between MT-3 positive (solid line) and MT-3 negative (dotted line)
bladder cancer patients. The data shows a statistically significant
difference (Log Rank 5.067, p = 0.024; Tarone-Ware 5.071; p = 0.024).
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modification.
The second goal of the study was to determine if the
accessibility of the MREs of the MT-3 promoter to a
transcription factor were different between the parental
UROtsa cell line and the UROtsa cell lines malignantly
transformed by either Cd
+2 or As
+3. The initial indica-
tion that the integrity of the MT-3 promoter may be
different between the parent and transformed UROtsa
cells, was that MT-3 mRNA expression could be further
induced by Zn
+2 in the transformed cell lines following
treatment with MS-275, but was not induced by an
identical treatment in the parental UROtsa cell line.
This observation was extended by an analysis of the
accessibility of the MREs within the MT-3 promoter to
binding of MTF-1. MTF-1 is a constitutively expressed
transcription factor that is activated by diverse stress sti-
muli, the most notable being metal load [10]. Upon sti-
mulation MTF-1 translocates to the nucleus where it
binds to the enhancers/promoters of target genes that
harbor one or multiple copies of the specific recognition
sequence, called MREs. The best characterized of these
target genes are the metallothioneins [11]. The analysis
was performed in the presence of 100 μMZ n
+2 because
Zn
+2 is necessary for the activation of MTF-1 and 100
μM is the concentration commonly utilized to deter-
mine MTF-1 activation. ChIP analysis showed that there
was no binding of MTF-1 to MREa and MREb of the
MT-3 promoter in the parental UROtsa cell line before
or after treatment with MS-275. In contrast, there was
MTF-1 binding to MREa and MREb of the MT-3 pro-
moter in the Cd
+2 and As
+3 transformed cell lines under
basal conditions, with a further increase in binding fol-
lowing treatment with MS-275. A similar analysis of
MTF-1 binding to MREc in the MT-3 promoter showed
the parental cells to have limited binding under basal
conditions and an increased interaction following treat-
ment with MS-275. In contrast, the Cd
+2 and As
+3
transformed cell lines were shown to have increased
binding of MTF-1 to MREc of the MT-3 promoter
under both basal conditions with no increase in interac-
tion following treatment with MS-275. An identical ana-
l y s i so fM R E e ,fa n dgo ft h eM T - 3p r o m o t e rw i t h
MTF-1 showed no interaction in the parental UROtsa
cell under basal conditions and an increase in binding
following treatment with MS-275. In contrast, MREe, f, g
of the MT-3 promoter were able to bind MTF-1 under
basal conditions, which was increased following treat-
ment with MS-275. These studies show that there is a
fundamental difference in the accessibility of MREs to
MTF-1 binding within the MT-3 promoter between the
parental UROtsa cells and the Cd
+2 and As
+3 trans-
formed cell lines. Under basal conditions, the MREs of
the MT-3 promoter are not accessible to MTF-1 binding
in the parental UROtsa cells. In contrast, the MREs of
the MT-3 promoter are accessible for MTF-1 binding
under basal conditions in the Cd
+2 and As
+3 transformed
cell lines.
Several common histone modifications, acetyl H4, tri-
methyl H3K4, trimethyl H3K27, and trimethyl H3K9,
associated with gene activation were analyzed in two
regions of the MT-3 promoter for the parental UROtsa
cells and the Cd
+2 and As
+3 transformed cell lines. The
level of histone H4 acetylation was always increased in
both the parental and transformed cell lines in the pre-
sence of MT-275. In addition, it was also found to be
increased in the more proximal region of the Cd
+2 and
As
+3 transformed cell lines not treated with MS-275 in
comparison to the parent cell line. The increase in H4
acetylation correlated with the increase in MT-3 expres-
sion and it is known that H4 acetylation is associated
with transcriptional activation [12-14]. The antibody
used for H4 acetylation does not distinguish among the
four potentially acetylated lysines 5, 8, 12, and 16, but
all are thought to be involved in transcriptional activa-
tion. Similarly, the above noted increases in MT-3
expression in the parental and transformed cell lines
also was associated with methylation of H3K4, which is
a modification also known to occur in promoters of
actively transcribing genes [12-14]. Together, these find-
ings give an indication that the MT-3 promoter in the
transformed cells has histone modifications that are
positive for transcription of the MT-3 gene. In contrast
to the above the findings which support a “transcription
ready” state, are the findings of increased histone H3K9
and H3K27 methylation, which are both associated with
a transcriptionally repressed state [12-14]. Taken
together, these findings can be interpreted to suggest
that the MT-3 promoter in the Cd
+2 and As
+3 trans-
formed cells has gained bivalent chromatin structure,
that is having elements of being “transcriptionally
repressed” and “transcription ready”, when compared to
parental UROtsa cells [15].
It has been shown previously that the Cd
+2 and As
+3
transformed cell lines have no expression of MT-3
mRNA under cell culture conditions, but gain MT-3
expression when transplanted as tumors in immune
compromised mice [2]. Based on the above histone
modifications in the cell lines, this finding would suggest
that transplantation of the Cd
+2 and As
+3 transformed
cell lines into an in vivo environment further alters the
chromatin structure of the MT-3 promoter to a state
capable of active transcription of the MT-3 gene. This
would suggest that the in vivo environment is providing
a factor/s that is capable of advancing bivalent chroma-
tin to a fully active state. There is no literature base that
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would be expected to be soluble or an insoluble compo-
nent of the cell matrix.
The last goal of this study was to perform a prelimin-
ary analysis to determine if MT-3 expression might
translate clinically as a possible biomarker for malignant
urothelial cells released into the urine by patients with
urothelial cancer. This was tested by the collection of
urothelial cells from the urine of patients attending their
regularly scheduled appointment in the urology clinic.
There was no clinical information available regarding
the possible exposure of the patients to metals. Urinary
cytologies were prepared using standard clinical labora-
tory methods and the cells subsequently immunostained
for MT-3 positive cells using an MT-3 antibody. The
hypothesis was that patients with urothelial cancer
would shed MT-3 positive cells into their urine and that
the shedding of MT-3 positive cells might identify
patients with urothelial cancer and also those whose dis-
ease had relapsed to an active state. The present diagno-
sis of urothelial cancer relies on the visual examination
of the bladder using a cystoscope. The results of the
present study did not support this initial hypothesis for
either newly diagnosed patients or for those being
assessed for recurrence of urothelial cancer. Urinary
cytology documented MT-3 positive cells in only a sub-
set of patients confirmed to have bladder cancer by
cystoscopy and also found many instances of MT-3
positive cells in patients having been diagnosed with
urothelial cancer and having no evidence of recurrence
upon cytoscopic examination. Despite not advancing the
initial hypothesis, there were some potentially important
findings in the study. First, it was shown that patients
without a diagnosis of urothelial cancer rarely had MT-
3 positive cells in their urine. The low rate in the con-
trol population is significant since these samples were
collected in the urology clinic and there are no or few
disease-free patients in such a specialized clinic. This
indicates a very low rate of MT-3 expression in indivi-
duals without urothelial cancer. Second, the results also
showed that a subset of urothelial cancer patients did
shed MT-3 positive cells into their urine and those with
more progressive urothelial cancer were more prone to
shed MT-3 positive cells. This may indicate that MT-3
staining in cytologies from newly diagnosed and recur-
rent urothelial cancer patients may have promise as a
prognostic marker for disease progression. There are
two rationales in support of this concept. The first is
that urinary cytology depends on the loss of strong cell-
to-cell contact between adjacent cells, allowing cells to
shed into the urine. As such, MT-3 positive cells in the
urine may define urothelial cancers where there has
been an extensive loss in cell-to-cell contact and interac-
tion with the surrounding tissue environment. These
w o u l db ee x p e c t e dt od e f i n em o r ea g g r e s s i v ec a n c e r s
prone to invasion of the bladder wall. A second related
rationale involves a field effect of “normal” tissue adja-
cent to the urothelial cancer that may have expression
of MT-3. This would explain the presence of MT-3
positive cells in the urine from individuals negative for a
recurrence of bladder cancer when examined by cyto-
scopy. The field effect would contain pre-malignant cells
that are positive for MT-3. A long term clinical follow-
up of current patients and further analysis of archival
tissue will be necessary to advance these possibilities.
Conclusions
This study shows that the MT-3 gene is silenced in non-
transformed urothelial cells by a mechanism involving
histone modification of the MT-3 promoter. In contrast,
transformation of the urothelial cells with either Cd
+2 or
As
+3 modified the chromatin of the MT-3 promoter to a
bivalent state of promoter readiness. Urinary cytology
demonstrated the presence of MT-3 positive cells in the
urine of some bladder cancers but did not correlate with
active disease status. It was rare to find MT-3 positive
cells in the urine from control subjects.
Methods
Cell culture
S t o c kc u l t u r e so ft h ep a r e n tU R O t s ac e l ll i n ea n dt h e
transformed Cd
+2 and As
+3cell lines were maintained in
75 cm
2 tissue culture flasks using Dulbecco’s modified
Eagles’ medium (DMEM) containing 5% v/v fetal calf
serum in a 37°C, 5% CO2: 95% air atmosphere [2]. Con-
fluent flasks were sub-cultured at a 1:4 ratio using tryp-
sin-EDTA (0.05%, 0.02%) and the cells were fed fresh
growth medium every 3 days.
Treatment of UROtsa cells with 5-Aza-2’-deoxycytidine
and histone deacetylase inhibitor MS-275
Parent and transformed UROtsa cells (10
6)were seeded
at a 1:10 ratio and the next day they were treated with 1
or 3 μM 5-AZC (Sigma-Aldrich, St. Louis, MO) or 1, 3
or 10 μM MS-275 (ALEXIS Biochemicals, Lausen, Swit-
zerland). The cells were allowed to grow to confluency
(48 h) and then harvested for RNA isolation. For the
exposure and recovery experiment, the cells were
exposed to 3 or 10 μM MS-275 until they reached con-
fluency (2-3 days), fed fresh media without drug for 24
h, and then dosed with 100 μMZ n S O 4(Sigma-Aldrich)
for 24 h and harvested for RNA isolation.
RNA isolation and RT-PCR analysis
Total RNA was isolated from the cells according to the
protocol supplied with TRI REAGENT (Molecular
Research Center, Inc., Cincinnati, OH) as described pre-
v i o u s l yb yt h i sl a b o r a t o r y[ 1 6 ] .R e a lt i m eR T - P C Rw a s
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levels utilizing a previously described MT-3 isoform-speci-
fic primer [16]. For analysis, 1 μg was subjected to comple-
mentary DNAsynthesis using the iScript cDNA synthesis
kit (Bio-Rad Laboratories, Hercules, CA) in a total volume
of 20 μl. Real-time PCR was performed utilizing the SYBR
Green kit (Bio-Rad Laboratories) with 2 μlo fc D N A ,
0.2 μM primers in a total volume of 20 μl in an iCycler iQ
real-time detection system (Bio-Rad Laboratories). Ampli-
fication was monitored by SYBR Green fluorescence and
compared to that of a standard curve of the MT-3 isoform
gene cloned into pcDNA3.1/hygro (+) and linearized with
Fsp I. Cycling parameters consisted of denaturation at
95°C for 30 s and annealing at 65°C for 45 s which gave
optimal amplification efficiency of each standard. The
level of MT-3 expression was normalized to that of
b-actin assessed by the same assay with the primer
sequences being sense, CGACAACGGCTCCGGCATGT,
and antisense, TGCCGTGCTCGATGGGGTACT, with
the cycling parameters of annealing/extension at 62°C for
45 s and denaturation at 95°C for 15 s. Semiquantitative
RT-PCR was also performed for MT- 3 expression using
the GeneAmp RNA PCR Kit (Applied Biosystem, Foster
city, CA) as described previously [17].
ChIP (Chromatin Immunoprecipitation) assay
ChIP assays were carried out using the ChIP-IT™
Express kit (Active Motif, Carlsbad, CA). The protocols
and reagents were supplied by the manufacturer.
UROtsa parent and the transformed cell lines were
seeded at 10
6 cells/75 cm
2 flask and 24 hrs later treated
with 10 μM MS-275. Following incubation for 48 hrs,
the cells were fixed with 1% formaldehyde for 10 min.
Cross linking was stopped by the addition of glycine
stop solution (0.125 M). The cells were scraped in 2 ml
phosphate buffered saline containing 0.5 mM PMSF.
The cells were pelleted and resuspended in ice cold lysis
buffer and homogenized in an ice-cold dounce homoge-
nizer. The released nuclei were pelleted and resus-
pended in a digestion buffer supplemented with PMSF
and protease inhibitor cocktail. The chromatin was
sheared using the enzymatic shearing cocktail at 37°C
for 5 min to an average length of 200-1500 bp. Approxi-
mately 7 μg of sheared chromatin was used to coat the
protein G-coated magnetic beads along with 3 μgo f
the antibody. The following antibodies were used in the
immunoprecipitations: MTF-1 (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA), Histone H3 trimethyl Lys9,
Histone H3 trimethyl Lys4, Histone H3 trimethyl Lys27,
(Active Motif) and Anti-acetyl-Histone H4 (Millipore,
Billerica, MA). The negative control IgG was purchased
from Active Motif. The coating was performed over-
night at 4°C following which the beads were washed and
the immune complexes were eluted using the elution
buffer and the cross linking was reversed using the
reverse cross linking buffer. The immunoprecipitated
DNA was analyzed by real time PCR using the iQ™
SYBR Green Supermix kit from Bio-Rad and semi quan-
titative PCR using the Gene Amp PCR core kit from
Applied Biosystems. The primers for the MT-3 promo-
ter were designed to span certain segments of the MT-3
promoter as depicted in Figure 4, and the sequences
and annealing temperatures are indicated in Table 2.
For quantitative PCR analysis, the quantity of the PCR
template found in each specific precipitate was normal-
ized to the amount of the corresponding DNA sequence
found in the fragmented chromatin solution present
before antibody-based precipitation (normalized to per-
centage of DNA input).
Urinary cytology and immunostaining for MT-3
The collection of urine and access to clinical data was
reviewed and approved by both the IRB at the Univer-
sity of North Dakota and the IRB of Sanford Health. All
participants signed an informed consent document. The
procedures for the collection of urine and preparation
for urinary cytology were identical to those procedures
used for clinical diagnosis of urinary samples in the
Sanford Health Urology Clinic and the Sanford Health
Cytology Laboratory in Fargo, ND. The Sanford Health
Laboratory is fully accredited by the College of Ameri-
can Pathologists (CAP) and meets all standards of the
Clinical Laboratory Improvement Act (CLIA). Briefly,
urine samples were accessioned with time and date
stamp upon arrival in the laboratory. Color, clarity and
amount were recorded for each sample. The sample was
centrifuged for 5 min at 2,000 rpm (Eppendorf 5810R)
and the specimen decanted, leaving cellular material and
Table 2 Sequences and PCR conditions for primers
Promoter regions Upper primer Lower primer Product size (bp) Annealing temperature °C
M R EA&B AAAGAGCGGGCGCGGTGC GACGCGCGGCTTGGCTAGTGG 111 75
MRE C GGCCCCGGCAGTGCACA GCGCACGCACTGCATCTGTCG 55 75
MRE E, F, G ATGGTACGTGCGCGCTTCC CATCCGCGTGCACGACCCACT 124 70
Region 1 GAACAGATCTGGCGTCCTG GCGCACGTACCATCTCCGA 111 63
Region 2 GTCGGGCTCATCGTGA ATTCTCCAGGACGCCAGAT 77 61
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was added and 2 to 5 ThinPrep
® slides prepared from
each sample. The slides were spray fixed immediately
after preparation and allowed to dry completely. Prior to
immunostaining, sections were immersed in preheated
Target Retrieval Solution (Dako, Carpinteria, CA) and
heated in a steamer for 20 minutes. The sections were
allowed to cool to room temperature and immersed into
Tris-buffered saline containing Tween 20 for 5 minutes.
The immunostaining was performed on a Dako autostai-
ner universal staining system. A primary anti-rabbit MT-
3 antibody generated and characterized by this laboratory
was used to localize MT-3 protein expression [2,18]. The
primary antibody was localized using the Dakocytoma-
tion EnVision+ System-HRP for rabbit primary antibo-
dies. Liquid diaminobenzidine was used for visualization
(DakoCytomation liquid DAB substrate chromogen sys-
tem). Slides were rinsed in distilled water, dehydrated in
graded ethanol, cleared in xylene, and coverslipped. The
presence and degree of MT-3 immunoreactivity was
judged by two pathologists. Sections of human kidney
served as a positive control for MT-3 staining.
Statistics
Statistical analysis for the promoter studies consisted of
ANOVA with Tukey post-hoc testing performed by
GraphPad PRISM 4. All statistical significance is
denoted at p < 0.05.
For the urine cytology experiments, statistical analysis
was performed with the aid of PASW Statistics 18
(SPSS, Inc., Chicago). Pearson Chi-square was used to
calculate the distribution of MT-3 positive or negative
counts in each group, as well as to evaluate the correla-
tions of frequency of MT-3 positive or negative between
each group. Kaplan-Meier method was applied for survi-
val analysis, Log-rank and Tarone-Ware tests were used
to analyze for statistical significance. A value of p < 0.05
was considered statistically significant.
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